Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
Epidermal growth factor receptor (EGFR) is a 170 kDa transmembrane glycoprotein receptor tyrosine kinase that, when activated by epidermal growth factor (EGF), affects cell growth and differentiation in normal and cancer cells (1). Binding of EGF or TGF alpha to EGFR activates tyrosine kinase activity of the receptor (2). The carboxy terminal tyrosine residues on EGFR, Tyr 1068, Tyr 1148, and Tyr 1173, are the major sites of autophosphorylation, which occurs as a result of EGF binding (3). EGFR overexpression is exhibited various cancer, such as glioma, colorectal carcinoma, breast carcinoma, and head and neck carcinoma (4). The phosphorylation level of EGFR is considered one of the important predicators for outcome in non-small cell lung cancer therapy (5).
Related Pathway
Adherens junction
Cytokine-cytokine receptor interaction
Delta-Notch Signaling Pathway
EGFR1 Signaling Pathway
Focal Adhesion
MAPK signaling pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
A. Western blot analysis on A431 cell lysate using anti-Phospho-EGFR (pY1068) RabMAb (catalog #1727-1), 1:1000 dilution. Cells were (1) untreated or (2) treated with EGF.
